Related Experiment Video
Updated: May 10, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sunitinib as an anti-endometriotic agent
Manal A Abbas1, Ahmad M Disi, Mutasem O Taha
1Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan. manabbas@yahoo.com
Summary
The anticancer drug sunitinib effectively treated endometriosis in a rat model, significantly reducing endometriotic implants. This suggests sunitinib may be a promising new therapy for endometriosis.
Area of Science:
- Gynecology
- Oncology
- Pathogenic Mechanisms
Background:
- Endometriosis is a common gynecological disease with limited effective treatments.
- The study highlights similarities between endometriosis and cancer pathogenesis.
- Current therapies for endometriosis are often unsatisfactory.
Purpose of the Study:
- To investigate the efficacy of sunitinib, an anticancer drug, in treating endometriosis.
- To explore sunitinib's potential as a novel therapeutic agent for endometriosis.
- To evaluate the impact of sunitinib on endometriotic implant regression.
Main Methods:
- A rat surgical model was utilized to study endometriosis.
- The effect of sunitinib on endometriotic implants was assessed.
- Histological analysis and TUNEL assay were performed to determine mechanisms of action.
Main Results:
- Sunitinib treatment reduced endometriotic cyst cross-sectional area by 78.8%.
- Complete disappearance of endometriotic cysts was observed in 50% of treated animals.
- Extensive fibrosis and apoptosis were detected in sunitinib-treated implants.
Conclusions:
- Sunitinib demonstrates significant efficacy in reducing endometriotic implants in a preclinical model.
- Apoptosis and fibrosis are identified as mechanisms underlying sunitinib's action in endometriosis.
- Sunitinib shows potential as a novel therapeutic strategy for managing endometriosis.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...